The ratio of phosphatidylcholines to lysophosphatidylcholines in plasma differentiates healthy controls from patients with Alzheimer's disease and mild cognitive impairment

[1]  A. Fagan,et al.  Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research , 2015, Alzheimer's & Dementia.

[2]  P. Sham,et al.  Plasma lipidomics analysis finds long chain cholesteryl esters to be associated with Alzheimer's disease , 2015, Translational Psychiatry.

[3]  J. Götz,et al.  Tau aggregation and its interplay with amyloid-β , 2014, Acta Neuropathologica.

[4]  B. Vissel,et al.  Inconsistencies and Controversies Surrounding the Amyloid Hypothesis of Alzheimer's Disease , 2014, Acta neuropathologica communications.

[5]  J. Malek,et al.  Metabolomics of Ramadan fasting: an opportunity for the controlled study of physiological responses to food intake , 2014, Journal of Translational Medicine.

[6]  J. Gómez-Ariza,et al.  Combination of metabolomic and phospholipid-profiling approaches for the study of Alzheimer's disease. , 2014, Journal of proteomics.

[7]  Derick R. Peterson,et al.  Plasma phospholipids identify antecedent memory impairment in older adults , 2014, Nature Medicine.

[8]  Simone Wahl,et al.  Targeted Metabolomics Identifies Reliable and Stable Metabolites in Human Serum and Plasma Samples , 2014, PloS one.

[9]  Joana Pinto,et al.  Human plasma stability during handling and storage: impact on NMR metabolomics. , 2014, The Analyst.

[10]  Erik Peter,et al.  Quality markers addressing preanalytical variations of blood and plasma processing identified by broad and targeted metabolite profiling. , 2014, Clinical chemistry.

[11]  H. Soininen,et al.  Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease , 2014, Neurobiology of Aging.

[12]  G. Kemmler,et al.  Analysis of 27 vascular-related proteins reveals that NT-proBNP is a potential biomarker for Alzheimer's disease and mild cognitive impairment: A pilot-study , 2014, Experimental Gerontology.

[13]  William A Banks,et al.  Blood–Brain Barrier Dysfunction as a Cause and Consequence of Alzheimer's Disease , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[14]  S. Niida,et al.  Lipidomic analysis of brain tissues and plasma in a mouse model expressing mutated human amyloid precursor protein/tau for Alzheimer’s disease , 2013, Lipids in Health and Disease.

[15]  T. Hankemeier,et al.  The influence of citrate, EDTA, and heparin anticoagulants to human plasma LC–MS lipidomic profiling , 2013, Metabolomics.

[16]  C. Caraguel,et al.  The two-step Fagan's nomogram: ad hoc interpretation of a diagnostic test result without calculation , 2013, Evidence-Based Medicine.

[17]  Waqar Ahmad.  Overlapped Metabolic and Therapeutic Links between Alzheimer and Diabetes , 2013, Molecular Neurobiology.

[18]  C. Gieger,et al.  Human serum metabolic profiles are age dependent , 2012, Aging cell.

[19]  Mattias Ohlsson,et al.  Evaluation of a Previously Suggested Plasma Biomarker Panel to Identify Alzheimer's Disease , 2012, PloS one.

[20]  H. Soininen,et al.  Metabolome in progression to Alzheimer's disease , 2011, Translational Psychiatry.

[21]  H. Tanila,et al.  From brain to food: analysis of phosphatidylcholins, lyso-phosphatidylcholins and phosphatidylcholin-plasmalogens derivates in Alzheimer's disease human post mortem brains and mice model via mass spectrometry. , 2011, Journal of chromatography. A.

[22]  F. Panza,et al.  Glycerophospholipids and glycerophospholipid-derived lipid mediators: a complex meshwork in Alzheimer's disease pathology. , 2011, Progress in lipid research.

[23]  Florian Kronenberg,et al.  Differences between Human Plasma and Serum Metabolite Profiles , 2011, PloS one.

[24]  Á. Simonyi,et al.  Phospholipases A2 and neural membrane dynamics: implications for Alzheimer’s disease , 2011, Journal of neurochemistry.

[25]  Georg Kemmler,et al.  Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease , 2011, Neurobiology of Aging.

[26]  Christian Humpel,et al.  Identifying and validating biomarkers for Alzheimer's disease , 2011, Trends in biotechnology.

[27]  P. He,et al.  Plasma metabolic profiling of Alzheimer's disease by liquid chromatography/mass spectrometry. , 2010, Clinical biochemistry.

[28]  Sylvain Arlot,et al.  A survey of cross-validation procedures for model selection , 2009, 0907.4728.

[29]  James C. Lee,et al.  Amyloid-beta peptide induces temporal membrane biphasic changes in astrocytes through cytosolic phospholipase A2. , 2008, Biochimica et biophysica acta.

[30]  T. J. Cunningham,et al.  Product inhibition of secreted phospholipase A2 may explain lysophosphatidylcholines' unexpected therapeutic properties , 2008, Journal of Inflammation.

[31]  R. Tibshirani,et al.  Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins , 2007, Nature Medicine.

[32]  C. Humpel,et al.  Cerebrovascular damage as a cause for Alzheimer's disease. , 2005, Current neurovascular research.

[33]  K. Blennow.  CSF biomarkers for mild cognitive impairment , 2004, Journal of internal medicine.

[34]  G. Casadesus,et al.  A Metabolic Basis for Alzheimer Disease , 2003, Neurochemical Research.

[35]  P. Scheltens,et al.  Decreased lysophosphatidylcholine/phosphatidylcholine ratio in cerebrospinal fluid in Alzheimer’s disease , 2003, Journal of Neural Transmission.

[36]  G. Kemmler,et al.  Sphingomyelin SM(d18:1/18:0) is significantly enhanced in cerebrospinal fluid samples dichotomized by pathological amyloid-β42, tau, and phospho-tau-181 levels. , 2015, Journal of Alzheimer's disease : JAD.

[37]  C. Antunez,et al.  A blood-based, 7-metabolite signature for the early diagnosis of Alzheimer's disease. , 2015, Journal of Alzheimer's disease : JAD.

[38]  Paul L Wood,et al.  Mass Spectrometry Strategies for Clinical Metabolomics and Lipidomics in Psychiatry, Neurology, and Neuro-Oncology , 2014, Neuropsychopharmacology.

[39]  Y. B. Wah,et al.  Power comparisons of Shapiro-Wilk , Kolmogorov-Smirnov , Lilliefors and Anderson-Darling tests , 2011 .

[40]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[41]  Joel R. Levin,et al.  A controlled, powerful multiple-comparison strategy for several situations. , 1994 .